Using the SPECTROstar Nano to identify biomarkers

November 24, 2011

The European ScreeningPort (ESP) is a Translational Research and Biomarker facility sited at the Centre for Molecular Neurobiology Hamburg (Zentrum für Molekulare Neurobiologie Hamburg, ZMNH).

Image of Dr EJ Dell
Dr EJ Dell
PhD, Sales Manager Northwest

The ZMNH is an internationally recognized research institute working on the molecular genetics, anatomical, biochemical, physiological and patho-physiological aspects of neurobiology, with a strong focus on multiple sclerosis (MS).

MS is an autoimmune disease leading to a chronic inflammation of the central nervous system.  Until now, the underlying cause of the disease has not been fully elucidated, but it can be modulated to limit disease progression and severity.

There is a clear need to identify biomarkers to support the development of superior therapeutics that can offer one or more of the following differentiating factors:

  • Improved efficacy and/or safety profile;
  • A novel mechanism of action;
  • A preferable route of administration over currently available therapies.

The proposed work summarized above will make use of the SPECTROstar Nano to allow the identification of biomarkers, using label free technology, which will subsequently allow an assessment to be made as to whether a patient will be a responder to a specific therapy for MS.

go to top